QTTB
Q32 BioDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The core bull case is that Q32 has narrowed the story to bempikibart, completed SIGNAL-AA Part B enrollment, and still guides to a mid-2026 topline readout while runway extends into late 2027 if management assumptions hold [#10-K-2026-03-10] [#PR-2026-03-10].
Posture
Defensive
Lead driver
Momentum
What changed
3 setup hits (3d) with net bullish as of 2026-06-02.
What can break
ATM usage could create incremental dilution and pressure sentiment.
Momentum
97
Value
41
Sentiment
0
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $5.50 · Bull $10.00 · Bear $2.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Bullish
Target $14.33
Why
Momentum97 · Δ7d +15.7
Value41 · Δ7d +0.1
Sentiment0 · Δ7d -45.2
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
97
34% active weight
Current posture
7d trendImproving
Δ7d
+15.7
Δ21d
+10.4
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendSoftening
Δ7d
-45.2
Δ21d
-52.4
Why this grade
Composite grade D. Momentum 97.0 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$197.71M
Beta
0.17
Shares Out
12.3M
P/E (TTM) · Derived
-3.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-5.06
Rev YoY
-100.0%
EPS YoY
+58.6%
Gross Margin
-
Op Margin
-
Net Debt
-$65.31M
Current Ratio
4.57
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology